Lincoln Pharmaceuticals Limited has informed the Exchange about Transcript of the investor meet held on February 18, 2026.
LINCOLN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lincoln Pharmaceuticals reported Q3 FY26 revenue of INR 166.32 crores (up ~13.5% YoY from INR 146.55 crores), EBITDA of INR 38.74 crores (up ~18.7%), net profit of INR 28.60 crores (up ~37.7%), and EPS of INR 14.28 (vs INR 10.37). Management reiterated its INR 1,000 crore long-term revenue target (originally FY28, may slip 5-6 months) and guided EBITDA margins to 15-18%, up from current ~15%. The Cepha block is expected to generate INR 45 crores this year with a target of INR 150 crores. Canada business is contributing $4-5 million with potential to reach $10-15 million. Exports contribute ~70% of revenue (Africa ~40%, LatAm/SE Asia ~25%, tender business ~15%, Canada and others the rest). Management plans to raise R&D spending from 1.8-2% to 2.3-3.25% and is exploring inorganic growth in tablet and injectable manufacturing, plus entry into oncology and hormones.
Strong Q3 print with margin expansion guidance and reiterated INR 1,000 crore target is positive for the stock. Near-term catalysts include EU reinspection by May-June 2026, Cepha block ramp-up, and Canada business growth. Inorganic growth plans, if executed, could accelerate the revenue target timeline. Shareholders should note dividend payout remains low as cash is being preserved for potential acquisitions.